<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901485</url>
  </required_header>
  <id_info>
    <org_study_id>08/H0708/16</org_study_id>
    <secondary_id>R&amp;D No. 2008/LF017B</secondary_id>
    <nct_id>NCT00901485</nct_id>
  </id_info>
  <brief_title>Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Newly Diagnosed Patients</brief_title>
  <official_title>Autotitrating Non-invasive Ventilation (NIV) Versus Standard NIV; a Randomised Crossover Trial in Patients With Newly Diagnosed Hypoventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ResMed</source>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the efficacy and tolerance of autotitrating non-invasive&#xD;
      ventilation (NIV) versus standard NIV in patients with newly diagnosed nocturnal&#xD;
      hypoventilation who have never experienced nocturnal, home NIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to compare the effect of two types of noninvasive ventilator (a small&#xD;
      machine that assists breathing) in patients newly diagnosed with nocturnal hypoventilation&#xD;
      who are inexperienced in the use of noninvasive ventilation (NIV). NIV is standard therapy&#xD;
      for patients with nocturnal hypoventilation.&#xD;
&#xD;
      The most common type of NIV is bilevel pressure support which assists patient breathing by&#xD;
      delivering different levels of air pressure during inspiration and expiration via a mask&#xD;
      covering the nose or nose and mouth. Standard bilevel NIV (VPAP™) has been further developed&#xD;
      to create a new automatically adjusting NIV (AutoVPAP™). Automatically adjusting NIV varies&#xD;
      the inspiratory air pressure according to the airflow rates generated by the patient. This&#xD;
      may improve patient comfort, hours of NIV use and recovery time.&#xD;
&#xD;
      Patients over the age of 18 referred to, or under follow up at, the Royal Brompton Hospital&#xD;
      who require domiciliary NIV but are inexperienced with use of NIV will be considered for&#xD;
      entry into this randomised crossover study. If eligible for inclusion and willing to take&#xD;
      part patients will be setup on automatically adjusting NIV or standard NIV, assigned in&#xD;
      random order. At the end of one month the patient will be swapped to the alternative NIV for&#xD;
      a further one month of domiciliary NIV treatment. At the end of each one month treatment&#xD;
      period the patient will undergo overnight polysomnography, transcutaneous CO2 monitoring and&#xD;
      24 hour Holter monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overnight Mean Oxygen Saturation</measure>
    <time_frame>4 weeks</time_frame>
    <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overnight Mean Transcutaneous Carbon Dioxide</measure>
    <time_frame>4 weeks</time_frame>
    <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overnight Peak Transcutaneous Carbon Dioxide</measure>
    <time_frame>4 weeks</time_frame>
    <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Desaturation Index (&gt;4%)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy. ODI is the number of events per hour that SaO2 drops by &gt;4%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality: Arousal Index</measure>
    <time_frame>4 weeks</time_frame>
    <description>A full PSG was performed during a sleep a on NIV at the end of each month's NIV therapy. Standard polysomnography analysis was performed by two team members blinded to patient identity and ventilator mode (REP/JJ).&#xD;
Sleep quality was assessed by the Arousal Index (no of arousals/hour)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ventilator Adherence</measure>
    <time_frame>4 weeks</time_frame>
    <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
  </other_outcome>
  <other_outcome>
    <measure>Median Overnight Minute Ventilation</measure>
    <time_frame>4 weeks</time_frame>
    <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
  </other_outcome>
  <other_outcome>
    <measure>Median Overnight Pressure Support</measure>
    <time_frame>4 weeks</time_frame>
    <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
  </other_outcome>
  <other_outcome>
    <measure>Median Overnight Tidal Volume</measure>
    <time_frame>4 weeks</time_frame>
    <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
  </other_outcome>
  <other_outcome>
    <measure>Median Overnight Respiratory Rated</measure>
    <time_frame>4 weeks</time_frame>
    <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective Ventilator Tolerance: Comfort of Breath Delivered</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective Ventilator Tolerance: Ease of Falling Asleep</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective Ventilation Tolerance: Ease of Use of Ventilator</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective Ventilator Tolerance: Liked Using Ventilator</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventilator Mode Preference</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Nocturnal Hypoventilation</condition>
  <condition>Neuromuscular Disease</condition>
  <condition>Chest Wall Disorder</condition>
  <arm_group>
    <arm_group_label>autotitrating NIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>approximately 6 weeks using domiciliary nocturnal autotitrating non-invasive ventilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard non-invasive ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>approximately 6 weeks using domiciliary nocturnal standard non-invasive ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AutoVPAP</intervention_name>
    <description>Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.</description>
    <arm_group_label>autotitrating NIV</arm_group_label>
    <other_name>autotitrating variable positive airway pressure</other_name>
    <other_name>autotitrating NIV</other_name>
    <other_name>automatically titrating NIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VPAPIIIST-A</intervention_name>
    <description>Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.</description>
    <arm_group_label>Standard non-invasive ventilation</arm_group_label>
    <other_name>standard NIV</other_name>
    <other_name>standard non-invasive ventilator</other_name>
    <other_name>variable positive airway pressure</other_name>
    <other_name>VPAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  new clinical diagnosis of nocturnal hypoventilation&#xD;
&#xD;
          -  requirement for long-term domiciliary non-invasive ventilation&#xD;
&#xD;
          -  no previous experience with domiciliary non-invasive ventilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled cardiac failure&#xD;
&#xD;
          -  acute exacerbation of respiratory failure&#xD;
&#xD;
          -  daytime resting PaO2 &lt; 7.5kPa&#xD;
&#xD;
          -  moderate or severe bulbar weakness&#xD;
&#xD;
          -  inability to understand rationale and/or consent form for study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Simonds, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield Hospital NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <results_first_submitted>April 14, 2021</results_first_submitted>
  <results_first_submitted_qc>May 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2021</results_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory insufficiency</keyword>
  <keyword>Hypercapnia</keyword>
  <keyword>Hypoventilation</keyword>
  <keyword>Sleep</keyword>
  <keyword>Polysomnography</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Titration</keyword>
  <keyword>Non Invasive Ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AutoVPAP Then VPAPIIIST-A</title>
          <description>All patients underwent a cross over design -&#xD;
1 month using domiciliary nocturnal standard non-invasive ventilation. (VPAPIIIST-A), and one month using AutoTitrating non-invasive ventilation</description>
        </group>
        <group group_id="P2">
          <title>VPAPIIIST-A First, Then AutoVPAP</title>
          <description>All patients underwent a cross over design -&#xD;
1 month using domiciliary nocturnal standard non-invasive ventilation. (VPAPIIIST-A), and one month using AutoTitrating non-invasive ventilation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>Patients underwent a cross over study design. In a randomised order they used 1 month of domiciliary nocturnal autotitrating, intelligent volume assured pressure support (iVAPS) non-invasive ventilation, and one month of standard non-invasive ventilation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="43" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 (forced expiratory volume) (L)</title>
          <units>L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" lower_limit="0.8" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC (forced vital capacity)</title>
          <units>L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" lower_limit="1.4" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC</title>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.75" lower_limit="0.64" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>maximal inspiratory effort (MIP) (cmH2O)</title>
          <units>cmH2O</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="30" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum expiratory pressure (MEP)</title>
          <units>cmH2O</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118" lower_limit="59" upper_limit="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>sniff nasal inspiratory pressure (SNIP)</title>
          <units>cmH2O</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="23" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overnight Mean Oxygen Saturation</title>
        <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overnight Mean Oxygen Saturation</title>
          <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy.</description>
          <units>% SaO2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="95" upper_limit="98"/>
                    <measurement group_id="O2" value="96" lower_limit="93" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We tested the hypothesis that iVAPS can ventilate a patient naive to NIV at least as effectively as standard PS.&#xD;
Sleep and breathing parameters at the end of each treatment period were compared using Wilcoxon Signed Rank test. The median difference between treatments with 95% confidence intervals was then compared by related-samples Hodges-Lehman test</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>To test for non-inferiority, a sample size of 36 (18 patients completing both arms of the crossover) was calculated to provide 80% power to detect a 2.5% drop in the primary outcome, mean overnight oxygen saturation (SpO2), with a SD of 3% at a significance level of 0.05</non_inferiority_desc>
            <p_value>0.13</p_value>
            <p_value_desc>a priori threshold for significance p&lt;0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overnight Mean Transcutaneous Carbon Dioxide</title>
        <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy.</description>
        <time_frame>4 weeks</time_frame>
        <population>All patients had a sleep study after 1 month of each mode of ventilation and all results are included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overnight Mean Transcutaneous Carbon Dioxide</title>
          <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy.</description>
          <population>All patients had a sleep study after 1 month of each mode of ventilation and all results are included in this analysis</population>
          <units>kPa</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="5.8" upper_limit="6.8"/>
                    <measurement group_id="O2" value="6.2" lower_limit="5.8" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis: that we tested the hypothesis that iVAPS, with automated selection of ventilator settings, was non-inferior to standard pressure support (PS) ventilation, with settings determined by an experienced healthcare professional, for controlling nocturnal hypoventilation in patients naïve to NIV.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>PtcCO2 is compared as a secondary outcome resulting in CO2 elimination similar to that of standard PS ventilation (median difference (95% CI) of -0.04(- 0.03 to 0.4)kPa in mean overnight PtcCO2).</non_inferiority_desc>
            <p_value>0.54</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overnight Peak Transcutaneous Carbon Dioxide</title>
        <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy.</description>
        <time_frame>4 weeks</time_frame>
        <population>All patients had a sleep study after 1 month of each mode of ventilation and all results are included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overnight Peak Transcutaneous Carbon Dioxide</title>
          <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy.</description>
          <population>All patients had a sleep study after 1 month of each mode of ventilation and all results are included in this analysis</population>
          <units>kPa</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.3" upper_limit="7.6"/>
                    <measurement group_id="O2" value="6.9" lower_limit="6.3" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.94</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Desaturation Index (&gt;4%)</title>
        <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy. ODI is the number of events per hour that SaO2 drops by &gt;4%.</description>
        <time_frame>4 weeks</time_frame>
        <population>All patients had a sleep study after 1 month of each mode of ventilation and all results are included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Desaturation Index (&gt;4%)</title>
          <description>Overnight oximetry (SaO2) and transcutaneous capnography (PtcCO2) (TOSCA, Linde Medical Sensors, Switzerland) were performed during a sleep a on NIV at the end of each month's NIV therapy. ODI is the number of events per hour that SaO2 drops by &gt;4%.</description>
          <population>All patients had a sleep study after 1 month of each mode of ventilation and all results are included in this analysis</population>
          <units>events/hr</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.3" upper_limit="12.2"/>
                    <measurement group_id="O2" value="5.0" lower_limit="1.5" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.42</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality: Arousal Index</title>
        <description>A full PSG was performed during a sleep a on NIV at the end of each month's NIV therapy. Standard polysomnography analysis was performed by two team members blinded to patient identity and ventilator mode (REP/JJ).&#xD;
Sleep quality was assessed by the Arousal Index (no of arousals/hour)</description>
        <time_frame>4 weeks</time_frame>
        <population>16 patients had comparative PSG data with all signals present for their sleep studies on both ventilator modes.</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality: Arousal Index</title>
          <description>A full PSG was performed during a sleep a on NIV at the end of each month's NIV therapy. Standard polysomnography analysis was performed by two team members blinded to patient identity and ventilator mode (REP/JJ).&#xD;
Sleep quality was assessed by the Arousal Index (no of arousals/hour)</description>
          <population>16 patients had comparative PSG data with all signals present for their sleep studies on both ventilator modes.</population>
          <units>events/hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="8" upper_limit="24"/>
                    <measurement group_id="O2" value="14" lower_limit="10" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.82</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ventilator Adherence</title>
        <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
        <time_frame>4 weeks</time_frame>
        <population>1 participant had missing adherence data and so was excluded from this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Adherence</title>
          <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
          <population>1 participant had missing adherence data and so was excluded from this analysis</population>
          <units>hh:mm/day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.40" lower_limit="4.42" upper_limit="6.49"/>
                    <measurement group_id="O2" value="4.20" lower_limit="2.27" upper_limit="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.0004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Overnight Minute Ventilation</title>
        <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
        <time_frame>4 weeks</time_frame>
        <population>2 patients had missing values from one of the ventilator modes, thus were excluded from the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overnight Minute Ventilation</title>
          <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
          <population>2 patients had missing values from one of the ventilator modes, thus were excluded from the analysis</population>
          <units>L/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="5.3" upper_limit="8.3"/>
                    <measurement group_id="O2" value="6.2" lower_limit="5.4" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.5</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Overnight Pressure Support</title>
        <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
        <time_frame>4 weeks</time_frame>
        <population>2 patients had missing data from one of the ventialtory modes and were excluded from the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overnight Pressure Support</title>
          <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
          <population>2 patients had missing data from one of the ventialtory modes and were excluded from the analysis</population>
          <units>cmH2O</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="5.6" upper_limit="10.4"/>
                    <measurement group_id="O2" value="10.0" lower_limit="9.0" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Overnight Tidal Volume</title>
        <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
        <time_frame>4 weeks</time_frame>
        <population>2 patients had missing data from one of the ventilatory modes and so were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overnight Tidal Volume</title>
          <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
          <population>2 patients had missing data from one of the ventilatory modes and so were excluded</population>
          <units>ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421" lower_limit="321" upper_limit="521"/>
                    <measurement group_id="O2" value="400" lower_limit="300" upper_limit="575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.47</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54</ci_lower_limit>
            <ci_upper_limit>23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Overnight Respiratory Rated</title>
        <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
        <time_frame>4 weeks</time_frame>
        <population>2 patients had missing data from one ventilatory mode and thus were excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overnight Respiratory Rated</title>
          <description>Summary data from the ventilators were downloaded after each month's therapy, including adherence (hours of use), and ventilator output (nightly mean pressure support, minute ventilation (MV), RR and leak).</description>
          <population>2 patients had missing data from one ventilatory mode and thus were excluded from analysis</population>
          <units>bpm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="13.2" upper_limit="18.4"/>
                    <measurement group_id="O2" value="15.5" lower_limit="13.5" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.41</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjective Ventilator Tolerance: Comfort of Breath Delivered</title>
        <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
        <time_frame>4 weeks</time_frame>
        <population>2 patients had missing data and thus were excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Ventilator Tolerance: Comfort of Breath Delivered</title>
          <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
          <population>2 patients had missing data and thus were excluded from analysis</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="55" upper_limit="91"/>
                    <measurement group_id="O2" value="72" lower_limit="45" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.36</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjective Ventilator Tolerance: Ease of Falling Asleep</title>
        <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
        <time_frame>4 weeks</time_frame>
        <population>2 patients had missing data and so were excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Ventilator Tolerance: Ease of Falling Asleep</title>
          <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
          <population>2 patients had missing data and so were excluded from analysis</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="69" upper_limit="94"/>
                    <measurement group_id="O2" value="79" lower_limit="60" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.59</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjective Ventilation Tolerance: Ease of Use of Ventilator</title>
        <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
        <time_frame>4 weeks</time_frame>
        <population>2 patients had missing data and were thus excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Ventilation Tolerance: Ease of Use of Ventilator</title>
          <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
          <population>2 patients had missing data and were thus excluded from analysis</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="77" upper_limit="95"/>
                    <measurement group_id="O2" value="86" lower_limit="78" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.59</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subjective Ventilator Tolerance: Liked Using Ventilator</title>
        <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
        <time_frame>4 weeks</time_frame>
        <population>2 patients had missing data, thus were excluded from analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Autotitrating iVAPS NIV</title>
            <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Standard Non-invasive PS Ventilation</title>
            <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Ventilator Tolerance: Liked Using Ventilator</title>
          <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
          <population>2 patients had missing data, thus were excluded from analysis</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="55" upper_limit="94"/>
                    <measurement group_id="O2" value="68" lower_limit="24" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>This is a secondary outcome</non_inferiority_desc>
            <p_value>0.72</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ventilator Mode Preference</title>
        <description>Subjective tolerance of ventilator modes was assessed by 10cm visual analogue scales (VAS) in response to questions on comfort of breath, ease of falling asleep, use of ventilator, and mode preference. VAS was scored from 0-100 for each question (0 - negative and 100 -s positive)</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored over the entire course of the trial; each participant was monitored throughout their participation of 2 months (1 month on each ventilator).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Autotitrating iVAPS NIV</title>
          <description>AutoVPAP: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of iVAPS NIV therapy.</description>
        </group>
        <group group_id="E2">
          <title>Standard Non-invasive PS Ventilation</title>
          <description>VPAPIIIST-A: Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.&#xD;
All completing patients used iVAPS in either period1 or period 2. The results are for all patients after the 1 month of standard PS NIV therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Miss Julia Kelly</name_or_title>
      <organization>Royal Brompton Hospital</organization>
      <phone>+44 2073528121 ext 4183</phone>
      <email>j.kelly@rbht.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

